Certolizumab Pegol Therapy for Rheumatoid Arthritis–Associated Scleritis

Purpose: To report the successful treatment of rheumatoid arthritis (RA)–associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol. Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process. Results: Six months after beginning the new therapy, it was well-tolerated and the patient's RA and scleritis were quiescent. Conclusions: Certolizumab pegol may successfully treat RA-associated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.

[1]  P. Emery,et al.  Aspects of TNF inhibitor therapy in rheumatoid arthritis , 2010, Modern rheumatology.

[2]  J. Restrepo,et al.  Successful treatment of severe nodular scleritis with adalimumab , 2010, Clinical Rheumatology.

[3]  N. Goel,et al.  Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study , 2008, Annals of the rheumatic diseases.

[4]  D. M. van der Heijde,et al.  Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial , 2008, Annals of the rheumatic diseases.

[5]  V. Strand,et al.  Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. , 2008, Arthritis and rheumatism.

[6]  A. Nesbitt,et al.  Mechanism of action of certolizumab pegol (CDP870): In vitro comparison with other anti‐tumor necrosis factor &agr; agents , 2007, Inflammatory bowel diseases.

[7]  P. Sfikakis,et al.  TUMOR NECROSIS FACTOR ANTAGONISTS: Preliminary Evidence for an Emerging Approach in the Treatment of Ocular Inflammation , 2007, Retina.

[8]  A. Galor,et al.  Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. , 2006, Ophthalmology.

[9]  P. Kiely,et al.  Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. , 2005, Rheumatology.

[10]  D. Korb,et al.  Lid Wiper Epitheliopathy and Dry Eye Symptoms , 2005, Eye & contact lens.

[11]  A. A. Drosos,et al.  Epidemiology of rheumatoid arthritis. , 2004, Autoimmunity reviews.

[12]  S. Pflugfelder,et al.  Recombinant Human Tumor Necrosis Factor Receptor Fc Fusion Protein (Etanercept): Experience as a Therapy for Sight-threatening Scleritis and Sterile Corneal Ulceration , 2004, Eye & contact lens.

[13]  S. Gabriel,et al.  Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years , 2003, Annals of the rheumatic diseases.

[14]  C. Bingham.  Emerging therapeutics for rheumatoid arthritis. , 2008, Bulletin of the NYU hospital for joint diseases.